ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Share repurchase program total authorization by Year
Share repurchase program total authorization ($M) ($M)
Eli Lilly Share repurchase program total authorization: $15,000M in FY2025, unchanged from a year earlier.
Latest, FY2025
15,000
Period ended Dec 31, 2025
Change on a year earlier
0.0%
15,000 in FY2024
History
3 years
Since FY2018
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Shareholders' Equity Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Share repurchase program total authorization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15,000 | 0.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 15,000 | – | Form 10-K (filed 2025-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 8,000 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Share repurchase program total authorization ($M), annual FY2018–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/buyback-program-auth
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.